RIMADYL Comprimé (à mâcher)

Country: Kanada

Lingwa: Franċiż

Sors: Health Canada

Ingredjent attiv:

Carprofène

Disponibbli minn:

ZOETIS CANADA INC

Dożaġġ:

25MG

Għamla farmaċewtika:

Comprimé (à mâcher)

Kompożizzjoni:

Carprofène 25MG

Rotta amministrattiva:

Orale

Unitajiet fil-pakkett:

7/60/180

Tip ta 'preskrizzjoni:

Prescription

Grupp terapewtiku:

Chiens

Sommarju tal-prodott:

Numéro de groupe d'ingrédients actifs (GIA) :0137034001

L-istatus ta 'awtorizzazzjoni:

APPROUVÉ

Data ta 'l-awtorizzazzjoni:

2002-09-16

Fuljett ta 'informazzjoni

NO COPY
NO COPY
NO COPY
NO COPY
NO COPY AREA
DESCRIPTION: Carprofen is a non-steroidal anti-inflammatory drug
(NSAID) of the propionic acid
class that includes ibuprofen, naproxen, and ketoprofen. The chemical
name for carprofen, a substi-
tuted carbazole, is (±)-6-chloro-α-methylcarbazole-2-acetic acid and
its structural formula is:
Carprofen is a white, crystalline compound with an empirical formula
of C
15
H
12
NO
2
Cl and a molecu-
lar weight of 273.72. It is freely soluble in ethanol, but practically
insoluble in water at 25°C.
CLINICAL PHARMACOLOGY: Carprofen is a non-narcotic, non-steroidal
anti-inflammatory agent
with characteristic analgesic and antipyretic activity approximately
equipotent to indomethacin in
animal models.
1
The mechanism of action of carprofen, like that of other NSAIDs, is
believed to be associated with
the inhibition of cyclooxygenase activity. Two unique cyclooxygenases
have been described in
mammals.
2
The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins
necessary for
normal gastrointestinal and renal function. The inducible
cyclooxygenase, COX-2, generates prosta-
glandins involved in inflammation. Inhibition of COX-1 is thought to
be associated with gastrointesti-
nal and renal toxicity while inhibition of COX-2 provides
anti-inflammatory activity. The specificity of
a particular NSAID for COX-2 versus COX-1 may vary from species to
species.
3
In an _in vitro_ study
using canine cell cultures, carprofen demonstrated selective
inhibition of COX-2 versus COX-1.
4
Clinical relevance of these data has not been shown.
Carprofen has also been shown to inhibit the release of several
prostaglandins in two inflammatory
cell systems: rat polymorphonuclear leukocytes (PMN) and human
rheumatoid synovial cells, indi-
cating inhibition of acute (PMN system) and chronic (synovial cell
system) inflammatory reactions.
1
Several studies have demonstrated that carprofen has modulatory
effects on both humoral and cel-
lular immune responses.
5–9
Data also indicate that carprofen i